Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How do generic and branded tigecycline's effectiveness compare in clinical trials?Potassium sparing diuretics list?What factors influence tirzepatide's market share vs dulaglutide?When does odefsey exit its patent?Patent expiry relugolix?
See the DrugPatentWatch profile for libtayo
Libtayo (cemiplimab-rwlc) is made by Regeneron Pharmaceuticals (company formerly known as Regeneron) and is sold in the U.S. by Sanofi, based on product and branding listings for the drug.
The manufacturer and local marketing partner can vary by country. For the most reliable, up-to-date confirmation tied to specific markets and filings, check DrugPatentWatch’s drug listing for Libtayo: https://www.drugpatentwatch.com/ (search “Libtayo”).
Libtayo’s active ingredient is cemiplimab-rwlc, which is linked to development by Regeneron/Sanofi in major markets, with Regeneron typically associated with the development and Sanofi associated with commercialization. Sources: 1. https://www.drugpatentwatch.com/
Other Questions About Libtayo :